ASKA Pharmaceutical Holdings Co (TSE:4886) Piotroski F-Score: 4 (As of Jul. 20, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4886 ASKA Pharmaceutical Holdings Co Ltd TSE:4886
61 GF Score
Price 円2,244.00
GF Value 円2,402.52
Valuation Fairly Valued
View Full Analysis

What is ASKA Pharmaceutical Holdings Co Piotroski F-Score?

ASKA Pharmaceutical Holdings Co TSE:4886 +1.40% 61 Piotroski F-Score is 4 as of Jul. 20, 2026, which is at its 10-year median of 4.00. GuruFocus rates TSE:4886 with a GF Score™ of 61/100 and a GF Value™ of 円2,402.52 (Fairly Valued). Among 979 Drug Manufacturers companies, ASKA Pharmaceutical Holdings Co ranks worse than 61.29% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ASKA Pharmaceutical Holdings Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Piotroski F-Score or its related term are showing as below:

TSE:4886' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 4   Max: 5
Current: 4

During the past 5 years, the highest Piotroski F-Score of ASKA Pharmaceutical Holdings Co was 5. The lowest was 4. And the median was 4.

ASKA Pharmaceutical Holdings Co  (TSE:4886) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ASKA Pharmaceutical Holdings Co Piotroski F-Score Related Terms


ASKA Pharmaceutical Holdings Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for ASKA Pharmaceutical Holdings Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ASKA Pharmaceutical Holdings Co Piotroski F-Score Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
N/A N/A 5.00 4.00 4.00

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 0.00 0.00 0.00 4.00

TSE:4886 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ASKA Pharmaceutical Holdings Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Piotroski F-Score falls into.


TSE:4886
61GF Score
ASKA Pharmaceutical Holdings Co Ltd TSE:4886
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 円5,424 Mil.
Cash Flow from Operations was 円6,303 Mil.
Revenue was 円71,127 Mil.
Gross Profit was 円34,145 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (104295 + 112379) / 2 = 円108337 Mil.
Total Assets at the begining of this year (Mar25) was 円104,295 Mil.
Long-Term Debt & Capital Lease Obligation was 円8,165 Mil.
Total Current Assets was 円61,424 Mil.
Total Current Liabilities was 円22,291 Mil.
Net Income was 円5,101 Mil.

Revenue was 円64,139 Mil.
Gross Profit was 円31,335 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (90745 + 104295) / 2 = 円97520 Mil.
Total Assets at the begining of last year (Mar24) was 円90,745 Mil.
Long-Term Debt & Capital Lease Obligation was 円6,441 Mil.
Total Current Assets was 円58,290 Mil.
Total Current Liabilities was 円22,879 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ASKA Pharmaceutical Holdings Co's current Net Income (TTM) was 5,424. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ASKA Pharmaceutical Holdings Co's current Cash Flow from Operations (TTM) was 6,303. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=5424/104295
=0.05200633

ROA (Last Year)=Net Income/Total Assets (Mar24)
=5101/90745
=0.05621246

ASKA Pharmaceutical Holdings Co's return on assets of this year was 0.05200633. ASKA Pharmaceutical Holdings Co's return on assets of last year was 0.05621246. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ASKA Pharmaceutical Holdings Co's current Net Income (TTM) was 5,424. ASKA Pharmaceutical Holdings Co's current Cash Flow from Operations (TTM) was 6,303. ==> 6,303 > 5,424 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=8165/108337
=0.07536668

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=6441/97520
=0.06604799

ASKA Pharmaceutical Holdings Co's gearing of this year was 0.07536668. ASKA Pharmaceutical Holdings Co's gearing of last year was 0.06604799. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=61424/22291
=2.75555157

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=58290/22879
=2.54775121

ASKA Pharmaceutical Holdings Co's current ratio of this year was 2.75555157. ASKA Pharmaceutical Holdings Co's current ratio of last year was 2.54775121. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ASKA Pharmaceutical Holdings Co's number of shares in issue this year was 28.38. ASKA Pharmaceutical Holdings Co's number of shares in issue last year was 28.347. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=34145/71127
=0.4800568

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=31335/64139
=0.48854831

ASKA Pharmaceutical Holdings Co's gross margin of this year was 0.4800568. ASKA Pharmaceutical Holdings Co's gross margin of last year was 0.48854831. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=71127/104295
=0.681979

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=64139/90745
=0.70680478

ASKA Pharmaceutical Holdings Co's asset turnover of this year was 0.681979. ASKA Pharmaceutical Holdings Co's asset turnover of last year was 0.70680478. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ASKA Pharmaceutical Holdings Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Piotroski F-Score of 4 as of Jul. 20, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. This is near median its historical median of 4.00. Over the past decade, ASKA Pharmaceutical Holdings Co's Piotroski F-Score has ranged from 4.00 to 5.00. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #600 out of 979 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is ASKA Pharmaceutical Holdings Co's Piotroski F-Score too high?
ASKA Pharmaceutical Holdings Co's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. ASKA Pharmaceutical Holdings Co's value of 4 is 20% below this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #600 out of 979 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #600 out of 979 companies for Piotroski F-Score. This places ASKA Pharmaceutical Holdings Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. ASKA Pharmaceutical Holdings Co's value of 4 is 20% below this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own Piotroski F-Score has ranged from 4.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, ASKA Pharmaceutical Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,402.52, compared to a current price of 円2,244.00 — trading 6.6% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Drug Manufacturers industry median of 5.00. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Piotroski F-Score is 4 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?

Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of 円2,244.00 is trading 6.6% below its estimated GF Value™ of 円2,402.52. GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.

Key valuation signals for TSE:4886:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: 円2,402.52 vs. price of 円2,244.00 (6.6% below fair value)
  • GF Score™: 61/100
  • Industry Position: 20% below the Drug Manufacturers median (#600 of 979)

No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ASKA Pharmaceutical Holdings Co Business Description

Address 2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
61GF Score

Get the complete analysis for TSE:4886

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,244.00
Price
円2,402.52
GF Value